Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Q3 2017 Earnings Presentation

17 slides from Avadel Pharmaceuticals's earnings presentation, Nov 8, 2017

  1. Slide 1: Q3 2017 Earnings Conference Call

    Q3 2017 Earnings Conference Call September 8, 2017

  2. Slide 2: Safe Harbor

    2 Safe Harbor This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, an

  3. Slide 3: Strategy Execution

    3 Strategy Execution Cash Generation Proprietary Product Development Business Development $39.7 Million Q3 Revenues $30 Million in Operating Cash Flow YTD REST-ON Phase III Trial of FT218, Micropump® Sodium Oxybate In-licensed Noctiva™ on September 1, 2017 Continued Growth Through Cash Generation, A

  4. Slide 4: Noctiva: First & Only FDA Approved Product to Treat Nocturia

    4 Noctiva™ First & Only FDA Approved Product to Treat Nocturia due to Nocturnal Polyuria in Adults Noctiva: Proprietary, low-dose (7 – 27x lower than existing forms), intranasal desmopressin acetate formulation Condition: Nocturia due to nocturnal polyuria causes patients to awaken 2 or more times /

  5. Slide 5: Hospital Products

    5 Hospital Products *Based on IMS data For full prescribing information for Bloxiverz, Vazculep and Akovaz, please see slide 17 of the appendix **AV001 is part of Avadel’s Unapproved Marketed Drug (UMD) strategy, for which it takes currently unapproved products through the FDA approval process Bloxi

  6. Slide 6: REST-ON Progress

    6 REST-ON Progress 5 of 6 sites active in Canada 24 of 31 sites active in US 16 of 18 sites active in Europe Additional sites to be added in US and UK Sodium Oxybate Naïve Criterion Remains High Hurdle During Screening Process For more details on our clinical trial, please visit www.rethinknarcoleps

  7. Slide 7: Non-GAAP Financial Results

    7 Non-GAAP Financial Results *Reconciliations from GAAP to Non-GAAP can be found in the appendix Three Months Ended (in 000s) 09/30/17 06/30/17 09/30/16 Sales $ 39,675 $ 47,411 $ 32,087 Cost of products and services sold 3,790 4,561 2,844 Research and development expenses 8,095 6,792 8,143 Selling,

  8. Slide 8: GAAP Financial Results

    8 GAAP Financial Results Three Months Ended (in 000s) 09/30/17 06/30/17 09/30/16 Sales $ 39,675 $ 46,311 $ 32,087 Cost of products and services sold 3,790 4,561 2,844 Research and development expenses 8,095 6,792 8,143 Selling, general and admin expenses 11,563 12,429 12,740 Intangible asset amortiz

  9. Slide 9: Revenues (GAAP)

    9 Revenues (GAAP) (in $000's) Q3 2017 Q2 2017 Q3 2016 Q3 2017 vs. Q2 2017 Q3 2017 vs. Q3 2016 Bloxiverz $ 9,920 $ 13,719 $ 15,591 $ (3,799) $ (5,671) Vazculep 9,573 10,154 9,340 (581) 233 Akovaz 18,561 20,912 5,568 (2,351) 12,993 Other 1,093 2,320 841 (1,227) 252 Total product sales and services 39,

  10. Slide 10: Cash Flow Summary

    10 Cash Flow Summary (in $000's) Nine Months Ended September 30, Total Cash and Marketable Securities 2017 2016 Beginning Balance 154,195 144,802 Operating Cash Flows (excl tax and earnout payments) 73,258 49,636 Earnout/Royalty Payments (29,136) (24,227) Income Taxes (14,605) (22,200) Acquisition o

  11. Slide 11: 2017 Non-GAAP Guidance

    11 2017 Non - GAAP Guidance 2017 Guidance Updated Previous Sales $165M - $175M $165M - $175M R&D Expense $30M - $35M $30M - $40M Income Tax Rate 55% - 65% 60% - 70% Diluted EPS (Adjusted) $0.25 - $0.35 $0.30 - $0.45

  12. Slide 12: Appendix

    12 APPENDIX

  13. Slide 13: GAAP to Non-GAAP Reconciliations (Q3 2017)

    13 GAAP to NON-GAAP Reconciliations GAAP to Non-GAAP adjustments for the three-months ended September 30, 2017 Exclude Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Restructuring impacts Contingent related party payable fair value adjustment Contingent related party payable

  14. Slide 14: GAAP to Non-GAAP Reconciliations (Q2 2017)

    14 GAAP to NON-GAAP Reconciliations GAAP to Non-GAAP adjustments for the three-months ended June 30, 2017 Exclude Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Restructuring impacts License revenue adj. Contingent related party payable fair value adjustment Contingent relat

  15. Slide 15: GAAP to Non-GAAP Reconciliations (Q3 2016)

    15 GAAP to NON-GAAP Reconciliations GAAP to Non-GAAP adjustments for the three-months ended September 30, 2016 Exclude Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value adjustment Contingent related party payable paid/accrued Total ad

  16. Slide 16: Noctiva Boxed Warning

    16 Noctiva™ (desmopressin acetate) Boxed Warning WARNING: HYPONATREMIA NOCTIVA can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death. NOCTIVA is contraindicated in patients at increased risk of severe hyponatremia, such as patien

  17. Slide 17: Product & Safety Information

    17 Product & Safety Information www.bloxiverz.com www.vazculep.com www.akovaz.com Full Prescribing & Safety Information www.karbinaler.com http://www.aciphexsprinkle.com http://cefaclororal.com http://flexichamber.com Akovaz® Bloxiverz® Vazculep® Noctiva™ Karbinal™ER Aciphex®Sprinkle™ Cefaclor Flexi

Avadel Pharmaceuticals — Q3 2017 Earnings Presentation on 6ix